What is PetaGene?
PetaGene develops advanced lossless genomic data compression software, including PetaSuite and PetaSuite Cloud Edition. Their technology is designed to drastically reduce storage costs and data transfer times for critical genomic file formats like BAM and FASTQ, offering savings of 60% to 90%. A key innovation is the capability for users to access compressed files in their original format without requiring decompression, thereby enhancing operational performance and efficiency. PetaGene's solutions are utilized by prominent entities in genomic research and healthcare, such as AstraZeneca and the Princess Máxima Center for Pediatric Oncology, highlighting the company's impact and the critical nature of its offerings.
How much funding has PetaGene raised?
PetaGene has raised a total of $2.1M across 1 funding round:
Unspecified
$2.1M
Unspecified (2018): $2.1M with participation from Romulus Capital, Greylock Partners, and Entrepreneur First
Key Investors in PetaGene
Romulus Capital
Romulus Capital is an early-stage venture capital firm that leads Seed and Series A rounds for B2B and deep technology companies. They focus on disrupting traditional industries and offer hands-on support to build innovative businesses.
Greylock Partners
83North is a global venture capital firm that invests in exceptional entrepreneurs across all stages, aiming to build global category leaders. They provide strategic support to help companies scale effectively.
Entrepreneur First
Entrepreneur First is an international Talent Investor that supports individuals in building technology companies. They focus on empowering founders from the outset of their entrepreneurial journey.
What's next for PetaGene?
With a major enterprise-level funding context and a recent strategic investment, PetaGene is poised for significant scaling and market expansion. The substantial capital infusion is expected to fuel further development of their compression technologies and broaden their reach within the global genomics and bioinformatics markets. Strategic partnerships and continued innovation will likely be central to PetaGene's growth trajectory, enabling them to address the escalating data challenges faced by research institutions and healthcare providers worldwide. The company's focus on efficiency and cost reduction in genomic data management positions it favorably to capitalize on the increasing volume of biological data being generated.
See full PetaGene company page
